E-Newsletter June 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Search
Search results
Gene Therapy improves functional measures in XLRP
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
Easter Fundraising
If you could use the long bank holiday weekend to fundraise for Retina UK, we would love to hear from you!
Webinar: Optician appointments explained: what to ask and why it matters
The latest webinar from Retina UK.
Joint statement on benefits and employment support
As a coalition of sight loss charities, we are calling on the Government to make the benefit system and employment support fit for purpose for blind and partially sighted people.
Webinar: Optician appointments explained: what to ask and why it matters
Join us for our upcoming webinar
e-Newsletter July 2025
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Podcast: Meet the Retina UK team
The latest podcast from Retina UK.
Nanoscope Announces topline results from randomised phase 2B trial of MCO-010 for retinitis pigmentosa
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
Meet a researcher: Chloe Brotherton
As part of our aim to nurture young scientists, we are very pleased to introduce one of our new PhD students as part of a co-funding agreement with the Macular Society.